A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Inclusion Criteria:

1. The subject is capable of understanding the informed consent form, voluntarilyparticipates, and signs the informed consent form;

2. No gender restrictions;

3. Age: ≥18 years and ≤75 years;

4. Expected survival time ≥3 months;

5. Patients with histologically confirmed non-Hodgkin's lymphoma;

6. Patients with relapsed or refractory non-Hodgkin's lymphoma (R/R NHL);

7. Presence of measurable lesions during the screening period (lymph node lesions withany long diameter ≥1.5 cm or extranodal lesions with any long diameter >1.0 cm);

8. ECOG performance status score ≤2;

9. Adverse reactions from prior anti-tumor treatment have recovered to ≤Grade 1 as perCTCAE 5.0 criteria;

10. Organ function levels meet the requirements before the first dose;

11. Female subjects of childbearing potential or male subjects with partners ofchildbearing potential must use highly effective contraception from 7 days beforethe first dose until 12 weeks after treatment discontinuation. Female subjects ofchildbearing potential must have a negative serum/urine pregnancy test within 7 daysbefore the first dose;

12. The subject has the ability and willingness to comply with the studyprotocol-specified visits, treatment plans, laboratory tests, and otherstudy-related procedures.

Exclusion Criteria:

1. Pulmonary diseases classified as ≥Grade 3 according to NCI-CTCAE v5.0; patientscurrently diagnosed with interstitial lung disease (ILD);

2. Active infections requiring systemic treatment, such as severe pneumonia,bacteremia, sepsis, etc.;

3. Active tuberculosis;

4. Patients with active autoimmune diseases;

5. History of other malignancies within 5 years prior to the first dose;

6. HBsAg-positive and/or HBcAb-positive with HBV-DNA levels ≥ the lower limit ofdetection; HCV antibody-positive with HCV-RNA levels ≥ the lower limit of detection;HIV antibody-positive;

7. Poorly controlled hypertension (systolic blood pressure >160 mmHg or diastolic bloodpressure >100 mmHg);

8. History of severe cardiovascular or cerebrovascular diseases;

9. Patients with a history of hypersensitivity to recombinant humanized antibodies orany excipients of GNC-038;

10. Pregnant or lactating women;

11. Patients with central nervous system involvement;

12. Major surgery within 28 days before the first dose of this study or planned majorsurgery during the study period;

13. Previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT);

14. Autologous hematopoietic stem cell transplantation (Auto-HSCT) within 12 weeksbefore initiating GNC-038 treatment;

15. Current use of immunosuppressive therapy;

16. Radiotherapy within 4 weeks before initiating GNC-038 treatment;

17. Chemotherapy or small-molecule targeted therapy within 2 weeks or 5 half-lives priorto treatment;

18. CAR-T therapy within 12 weeks before initiating GNC-038 treatment;

19. Use of any other investigational drug in a clinical trial within 4 weeks or 5half-lives before the first dose of this study;

20. Any other condition deemed unsuitable for participation in this clinical trial bythe investigator.